Defining mechanisms of resistance to Src inhibitors in thyroid cancer
MetadataShow full item record
Advanced stages of papillary and anaplastic thyroid cancer continue to be plagued by a dismal prognosis, which is a result of limited effective therapies for these cancers. This predicament has spawned an influx of research defining the signaling mechanisms that promote the progression and aggressiveness of late stage thyroid cancers. Due to the high proportion of thyroid cancers harboring mutations in the MAPK pathway, the MAPK pathway has become a focal point for therapeutic intervention in thyroid cancer. Unfortunately, unlike melanoma, a similar responsiveness to MAPK pathway inhibition ...